X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Nicholas Piramal: Roche blues for now - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Oct 25, 2004

    Nicholas Piramal: Roche blues for now

    Introduction to results
    Domestic pharma major, Nicholas Piramal, has declared its 2QFY05 and 1HFY05 results. In the quarter, the topline of the company has grown by 2%, while the net profit increased by 7% led by expansion of operating margin, which stood at 21.9%. In the first half of current financial year, the net profit has increased by 25.1%, while topline is down marginally.

    (Rs m) 1QFY04 1QFY05 Change 1HFY04 1HFY05 Change
    Net sales 3,684 3,757 2.0% 7,456 7,347 -1.5%
    Expenditure 2,927 2,934 0.2% 5,890 5,872 -0.3%
    Operating profit (EBDITA) 757 824 8.8% 1,566 1,475 -5.8%
    Operating profit margin (%) 20.5% 21.9%   21.0% 20.1%  
    Other income 48 64 34.5% 99 101 2.5%
    Interest 36 49 37.2% 144 72 -50.0%
    Depreciation 99 121 21.7% 297 229 -22.8%
    Exceptional Items 35 23   156 23  
    Profit before tax 635 695 9.5% 1,067 1,252 17.3%
    Tax 112 135 20.8% 265 248 -6.5%
    Profit after tax/(loss) 523 560 7.0% 802 1,004 25.1%
    Net profit margin (%) 14.2% 14.9%   10.8% 13.7%  
    No. of shares (m) 38.0 38.0   38.0 38.0  
    Diluted earnings per share (Rs)* 55.1 58.9   42.2 52.8  
    P/E ratio (x)         18.5  
    (* annualised)            

    What’s the company’s business?
    Nicholas Piramal is one of the leading Indian pharma companies with strong focus in the domestic market. It is the 4th largest company with 4.3% market share in the domestic retail market with a large sales force covering 10 therapeutic segments of the pharma industry. The company has started focusing on the exports market too and the contribution of exports in total sales has increased to 11% from zero in two years time. With its differentiated exports strategy, the company is going to benefit from its cost competitiveness.

    What has driven performance in 1QFY05?
    Sales:  The sales growth remained subdued in the current quarter. The major reason for this dismal performance is discontinuation of its distribution arrangement for certain diagnostic products of Roche (sales of about Rs 720 m in FY04). Roche will pay US$ 22 m to the company as compensation for the discontinuation of agreement for exclusive distribution. Apart from this, the company has also discontinued distribution and production of six biotech products of Roche (sales about Rs 200 m in FY04).

    If we remove the effect of this, the revenue has grown by about 13% in the quarter and 16.5% in the first half of FY05, on a like to like basis. In domestic market, the formulations revenue of the company has grown by almost 6%, which is marginally lower than the industry growth (7%). However, Nicholas has launched 13 new products in the quarter and growth from these brands is likely to come in next few quarters. On exports front, revenues have grown by 67% led by growth in vitamins and bulk drugs exports. However, the sales of vitamins and bulk drugs in domestic market have come down by 39% and 87% YoY respectively.

    Operating margins:  The operating margins of the company have gone up by 140 basis points. The discontinuation of Roche's diagnostic equipment distribution business has helped in improving the margins, as it was a low margin distribution business. Apart from that, the improved product mix has helped the company to increase its margins despite increase in staff cost and R&D expenditure. The major savings has come from decrease in material cost, which is function both inventory adjustment and discontinuation of Roche diagnostic distribution business.

    Cost break-up
      1HFY04 1HFY05 Change
    Raw Material 3,314 2,977 -10.2%
    (as % of sales) 44% 41%  
    Staff Cost 794 829 4.3%
    (as % of sales) 11% 11%  
    R&D Expenses 110 212 92.7%
    (as % of sales) 1% 3%  
    Other Expenditure 1,672 1,854 10.9%
    (as % of sales) 22% 25%  
    Total 5,890 5,872 -0.3%

    Net profit:  The net profit of the company has grown by 7%, which is largely driven by the savings on the operational front. Depreciation charge in the quarter has gone up considerably, due to new facilities becoming operational. The tax provision has also increased in the current quarter.

    What to expect?
    Nicholas Piramal is a leading company in the pharmaceutical industry, although its past has been marred by choppy topline and bottomline performance. At Rs 978, the stock is trading 18.5x annualised 1HFY05 earnings. While currently, domestic formulations business is the major revenue driver for the company, going forward contract manufacturing is going to be the key driver. However, contract manufacturing is a low value addition business. Currently, the company is entering into an agreement for contract manufacturing at very high margins (operating margins 25%) owing to its low labour and overheads costs. However, these margins may not be sustainable in the long run. After all European contract manufacturers work at single digit margins!

     

     

    Equitymaster requests your view! Post a comment on "Nicholas Piramal: Roche blues for now". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

    Aug 8, 2017

    'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    PIRAMAL ENTERPRISES SHARE PRICE


    Aug 21, 2017 (Close)

    TRACK PIRAMAL ENTERPRISES

    • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    MORE ON PIRAMAL ENTERPRISES

    PIRAMAL ENTERPRISES - ACTAVIS COMPARISON

    Compare Company With Charts

    COMPARE PIRAMAL ENTERPRISES WITH

    MARKET STATS